Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
Journal of the American Academy of Dermatology|March 1, 1986
Diagnosis of the dysplastic nevus in different populationsG C Roush, R L Barnhill, P H Duray, et al.
Cancer Research|February 15, 1988
Dysplastic nevi in association with multiple primary melanomaL Titus-Ernstoff, P H Duray, M S Ernstoff, et al.
Clinical Nuclear Medicine|April 1, 1988
Intrapatient and interpatient comparison of tumor size and monoclonal antibody uptake in melanomaE A Cornelius, R D Neumann, S S Zoghbi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684J M Kirkwood, M H Strawderman, M S Ernstoff, et al.
The Journal of Urology|July 20, 1999
In vivo description of dendritic cells in human renal cell carcinomaT Schwaab, A R Schned, J A Heaney, et al.
Bone Marrow Transplantation|April 10, 2007
Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myelomaK R Meehan, J Wu, E Bengtson, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|April 1, 1991
Granulocytopenia in cancer patients treated in a phase I trial with recombinant human tumor necrosis factorT F Logan, S S Kaplan, J L Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J M Kirkwood, M H Strawderman, M S Ernstoff, et al.
Journal of the National Cancer Institute|December 2, 1992
Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factorT F Logan, M A Virji, W E Gooding, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|October 1, 1991
Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cellsP Sedlmayr, H Rabinowich, E M Elder, et al.
Pageof 9